s&o logo
  • News
  • Trade Ideas
  • Education
  • Community
Sign Up!
Featured, News, Trade Ideas

Quantum BioPharma’s unbuzzd™ Shows Promising Results in Reducing Alcohol Intoxication and Hangover Symptoms

February 4, 2025 Elisa Clay No comments yet

Quantum BioPharma (NASDAQ: QNTM) announced compelling results from a clinical trial evaluating its dietary supplement, unbuzzd. The double-blind, randomized, placebo-controlled study demonstrated that unbuzzd significantly accelerates alcohol metabolism, lowers blood alcohol concentration (BAC), and reduces symptoms of intoxication and hangovers.

Participants in the trial, aged 21 to 43, experienced a rapid reduction in BAC—more than 40% faster than those given a placebo. These effects were noticeable within 30 minutes of consuming the supplement and sustained over a four-hour period. In addition to faster alcohol metabolism, participants reported improved alertness and cognitive performance, with fewer errors and reduced mental fatigue compared to the placebo group.

Physiological benefits were also evident. unbuzzd stabilized heart rate and blood pressure, counteracting typical alcohol-induced fluctuations. Hangover symptoms, particularly headaches, were notably reduced by 67% at the four-hour mark and continued to decrease eight hours post-consumption.

“We are thrilled to see such significant and meaningful outcomes in this clinical study,” said Dr. Andrzej Chruscinski, Vice President of Clinical and Scientific Affairs at Quantum BioPharma. “The results confirm unbuzzd™’s exceptional performance in reducing the acute effects of alcohol intoxication.”

Importantly, unbuzzd was well-tolerated by all participants, with no reported side effects, reinforcing its safety profile.

Zeeshan Saeed, CEO of Quantum BioPharma, emphasized the supplement’s role in promoting responsible alcohol consumption. “This clinical trial shows that unbuzzd is an important addition to the safe and responsible consumption of alcohol. Consumers now have the benefit of knowing that unbuzzd can reduce alcohol intoxication, speed the reduction of blood alcohol concentration, restore mental alertness, and help them avoid the worst symptoms of a hangover,” Saeed said.

The study’s promising results position unbuzzd as a breakthrough product in the wellness and dietary supplement market, offering consumers an innovative solution to mitigate the effects of alcohol consumption.

You might like this article: GH Research Achieves Breakthrough with Ultra-Rapid Antidepressant GH001 in Phase 2b Trial

  • QNTM
  • Quantum BioPharma
  • Stock Market
  • Stocks

Post navigation

Previous
Next

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

Categories

  • Education (15)
  • Featured (46)
  • News (85)
  • Trade Ideas (39)

Recent posts

  • FDA Closes Inspection of BioXcel’s TRANQUILITY II Trial Site, Reinforcing Data Integrity
  • Telomir Pharmaceuticals Breakthrough in Silver-Based Medicine
  • flyExclusive to Acquire Jet.AI’s Aviation Business in Strategic Expansion

Tags

BDRX CDT Conduit Conference Call CURR CURRENC Earnings Evergreen GH Research GHRS Grail GRAL HOLO IINN Inspira Technologies Interview IPWR JTAI KULR LCID Litigation LLY Lucid Motors M&A MedTech MicroCloud Movers MSTR My Size MYSZ News NLSP Novo Nordisk NVO Options Partnerships QNTM Quantum BioPharma Stock Market Stocks TAOP TELO Telomir Pharmaceuticals Traws Pharma TRWS

Continue reading

Featured, News, Trade Ideas

FDA Closes Inspection of BioXcel’s TRANQUILITY II Trial Site, Reinforcing Data Integrity

March 3, 2025 Elisa Clay No comments yet

BioXcel Therapeutics (BTAI) announced that the U.S. Food and Drug Administration (FDA) has officially closed its inspection of a single site involved in the TRANQUILITY II Phase 3 trial under 21 C.F.R.20.64(d)(3). The FDA’s designation of “Voluntary Action Indicated” (VAI) signals that while minor issues may have been identified, no regulatory action is required, further […]

Featured, News, Trade Ideas

Telomir Pharmaceuticals Breakthrough in Silver-Based Medicine

February 20, 2025 Elisa Clay No comments yet

Telomir Pharmaceuticals (NASDAQ: TELO) has achieved a major scientific breakthrough by stabilizing Silver(II) (Ag²⁺) using its proprietary compound, Telomir-1. This advancement overcomes a key challenge in silver-based medicine, unlocking new possibilities for antimicrobial treatments, wound care, and infection-resistant medical coatings. Silver(II) offers superior antibacterial action, faster wound healing, and immune-modulating properties compared to traditional Silver(I) […]

Featured, News, Trade Ideas

flyExclusive to Acquire Jet.AI’s Aviation Business in Strategic Expansion

February 14, 2025 Elisa Clay No comments yet

flyExclusive (NYSE American: FLYX), a leading provider of premium jet charter experiences, has entered into a definitive agreement to acquire the aviation business of Jet.AI (NASDAQ: JTAI). The deal will allow flyExclusive to expand its fleet and market presence while enabling Jet.AI to transition into a pure-play AI solutions company. Under the terms of the […]

s&o logo

Our primary goal is to empower retail investors with helpful news, guides and trading ideas.

Helpful Links
  • News
  • Trade Ideas
  • Education
  • Community
Resources
  • Privacy Policy
  • Terms & Conditions
  • Contact
Get in touch
  • Email us!

© Copyright 2024, stocks&options. All Rights Reserved.